

Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice

Citation for published version (APA):

Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A., Wessels, H. J., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., & Robillard, M. S. (2019). Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice: (Nature Communications, (2018), 9, 1, (1484), 10.1038/s41467-018-03880-y). *Nature Communications*, 10(1), Article 363. <https://doi.org/10.1038/s41467-019-08376-x>

DOI:

[10.1038/s41467-019-08376-x](https://doi.org/10.1038/s41467-019-08376-x)

Document status and date:

Published: 16/01/2019

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

<https://doi.org/10.1038/s41467-019-08376-x>

OPEN

Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice

Raffaella Rossin¹, Ron M. Versteegen², Jeremy Wu³, Alisher Khasanov⁴, Hans J. Wessels⁵, Erik J. Steenbergen⁶, Wolter ten Hoeve⁷, Henk M. Janssen², Arthur H.A.M. van Onzen¹, Peter J. Hudson³ & Marc S. Robillard¹

Correction to: *Nature Communications*; <https://doi.org/10.1038/s41467-018-03880-y>; published online 04 May 2018.

The original version of this Article omitted the following from the Acknowledgements: ‘This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program under Award No. W81XWH-15-1-0692. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense’. This error has now been corrected in the PDF and HTML versions of the Article.

Published online: 16 January 2019



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

¹Tagworks Pharmaceuticals, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. ²SyMO-Chem B.V., Den Dolech 2, 5612 AZ Eindhoven, The Netherlands. ³Avipec Pty Ltd, 343 Royal Parade, Parkville, VIC 3052, Australia. ⁴Levena Biopharma, 4955 Directors Place, Suite 300, San Diego, CA 92121, USA. ⁵Radboud Proteomics Centre, Department of Laboratory Medicine, Radboud University Medical Center, P.O. Box 91016500 HB Nijmegen, The Netherlands. ⁶Department of Pathology, Radboud University Medical Center, P.O. Box 91016500 HB Nijmegen, The Netherlands. ⁷Syncom B.V., Kadijk 3, 9747 AT Groningen, The Netherlands. Correspondence and requests for materials should be addressed to M.S.R. (email: marc.robillard@tagworkspharma.com)